• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Low-dose alteplase did not show differential benefits across age, ethnicity or severity of stroke compared with standard-dose

byShayna BejaimalandAnees Daud
October 10, 2017
in Cardiology, Chronic Disease, Emergency, Imaging and Intervention, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this secondary analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), there were no significant difference in treatment effects between low and standard-dose alteplase for death or disability in acute ischemic stroke across age, ethnicity, or severity.

2. This trial did show that there were fewer symptomatic intracerebral hemorrhages in the low-dose alteplase group, however the risk also did not differ significantly across age, ethnicity or severity.

Evidence Rating Level: 3 (Average)

Study Rundown: Alteplase is used for thrombolysis in acute ischemic stroke (AIS). Previous studies have shown that lower doses of alteplase result in a lower risk of symptomatic intracerebral hemorrhage however it remains unclear in whom lower doses may provide the most benefit as compared to standard-dose intravenous alteplase. This secondary analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) aimed to assess the treatment effects of low-dose versus standard-dose intravenous alteplase and their association with age, ethnicity (Asian vs. non-Asian) and severity of AIS.

There were no significant differences in the treatment effects between low and standard-dose alteplase for poor outcome (defined as death or disability) at 90 days across age, ethnicity or severity. Results were similar for functional outcomes also, showing no difference between low- and standard-dose alteplase. There were reductions in the rate of symptomatic intracerebral hemorrhage with low-dose alteplase however this did not differ significantly across age, ethnicity or severity. Strengths of this study include analysis of a large sample with good follow-up and treatment adherence however the initial trial was performed in a majority of Asian ethnicity and thus may impact generalizability to North American populations.

Click to read the study, published in JAMA Neurology

Relevant Reading: Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke (ENCHANTED)

RELATED REPORTS

Intravenous tenecteplase non-inferior to alteplase for patients with acute ischemic strokes

Left atrial strain and left atrial strain rate independently associated with risk of ischemic stroke in older adults

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

In-Depth [secondary analysis]: This study was a prespecified secondary analysis of the ENCHANTED trial. The ENCHANTED trial was an international, randomized, open-label, blinded, clinical trial that compared low-dose vs. standard-dose intravenous alteplase for patients with AIS. It took place between March 2012 and August 2015 and included patients with clinical and image confirmed AIS who were eligible for thrombolysis. Patients were randomized to low dose (0.6 mg/kg; 15% as bolus and 85% over 1 hour infusion) or standard dose (0.9mg/kg; 10% as bolus and 90% over 1 hour infusion). The secondary analysis was conducted between May 2016 and April 2017. Primary outcomes of interest for the secondary analysis included death and disability as scored by the modified Rankin Scale at 90 days. Logistical regression models with statistical testing for interaction were used for this secondary analysis.

The ENCHANTED study included 3310 patients with clinical and imaging evidence of AIS, of which 3297 patients were used for this secondary analysis. There were no significant differences in treatment effects found between low-dose or standard-dose alteplase across age, ethnicity (Asian vs. non-Asian) or severity, all p >0.37 for interaction. Results were similar for functional outcomes also, showing no difference between low- and standard-dose alteplase. Reductions in symptomatic intracerebral hemorrhages also were seen in the low-dose group however these reductions did not differ statistically across age, ethnicity or severity of AIS.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alteplaseischemic stroke
Previous Post

Coronary CT angiography linked to increased intervention, decreased myocardial infarction

Next Post

Ibuprofen as effective as morphine for pediatric musculoskeletal injury pain

RelatedReports

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Intravenous tenecteplase non-inferior to alteplase for patients with acute ischemic strokes

March 7, 2023
Patient Basics: Atrial Fibrillation
Cardiology

Left atrial strain and left atrial strain rate independently associated with risk of ischemic stroke in older adults

February 16, 2023
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes
StudyGraphics

#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes

November 24, 2022
Next Post
Child maltreatment associated with poor adult socioeconomic status

Ibuprofen as effective as morphine for pediatric musculoskeletal injury pain

Development of a risk index for colorectal cancer screening

Evidence suggests that patient navigators and provider reminders may improve follow-up after positive fecal blood test

Live attenuated vaccine less effective in recent influenza season

2 Minute Medicine Rewind October 9, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Synergistic interaction between risk burden and genetics for atrial fibrillation development
  • Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options